L O W E R R E S P I R A T O R Y T R A C T D I S O R D E R S a n d M E D I C A T I O N S

Pathophysiology and Manifestations of Asthma

• Definition and Basic Pathophysiology:

  • Asthma is an obstructive airway disease characterized by airway narrowing that traps air in the lungs, preventing efficient exhalation.

  • It is driven by an underlying inflammatory process that leads to airway edema and excess mucus production, ultimately resulting in severe bronchospasm.

  • Immunological Mechanism: It is an $\text{IgE}$-mediated immune response. Exposure to triggers causes histamines and leukotrienes to flood the airway, inducing smooth muscle constriction and mucosal inflammation.

  • Airway Remodeling: Chronic, unmanaged asthma can cause permanent structural changes in the airway (airway remodeling), leading to persistent, long-term narrowing.

• Airway Structural States:

  • Normal Airway: Features relaxed smooth muscles and a wide, open lumen.

  • Asthmatic Airway: Characterized by an inflamed airway lining and mucus accumulation, though smooth muscles may remain partially relaxed.

  • Status Asthmaticus Airway: Features severely tightened smooth muscles (bronchospasm) surrounding an intensely inflamed, swollen, and mucus-clogged lumen.

• Asthma Subtypes:

  • Allergic Asthma: The most common type; typically begins in childhood. Frequently manifests alongside skin eczema (on extremities, back, chest), allergic rhinitis (chronic runny nose), food allergies, or drug allergies (e.g., amoxicillin).

  • Nonallergic Asthma: More common in adults; not triggered by specific environmental allergens.

  • Aspirin-Sensitive Asthma: Occurs in adults or children who experience severe wheezing and airway narrowing after ingesting aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs).

  • Exercise-Induced Asthma: Symptoms occur specifically during physical exertion due to hyperventilation-induced airway cooling, inflammation, and excess mucus. Clients can premedicate with an inhaler prior to exercise to prevent symptoms.

• Risk Factors:

  • Genetic: Family history of allergies or asthma; sex-based differences (incidence varies between males and females depending on age group).

  • Environmental: Chronic upper respiratory infections, urban air pollution, and exposure to cold air.

  • Triggers: Cigarette smoke, pollen, dust mites, chemical fumes, and emotional stress.

  • Comorbidities: Obesity, Gastroesophageal Reflux Disease (GERD), Obstructive Sleep Apnea (OSA), and chronic rhinitis.

• Clinical Presentation and Symptoms:

  • Coughing (frequently worsens at night).

  • Expiratory wheezing (high-pitched whistling sound heard on exhalation).

  • Inspiratory retractions (visible intercostal or abdominal muscle pulling on inhalation).

  • Tachypnea (increased respiratory rate) and dyspnea (shortness of breath).

  • Chest tightness caused by extreme work of breathing against narrowed airways.

  • Tachycardia (compensatory increase in heart rate to maintain oxygen delivery).

  • Anxiety and agitation stemming from hypoxia and air hunger.

  • Increased daytime sleepiness resulting from nocturnal coughing and awakenings.

• Asthma Severity Classifications:

  • Intermittent Asthma: Symptoms occur $<2\text{ days/week}$; nighttime awakenings from coughing occur $<2\text{ nights/month}$.

  • Mild Persistent Asthma: Symptoms occur $>2\text{ days/week}$; nighttime awakenings occur $3\text{--}4\text{ times/month}$.

  • Moderate Persistent Asthma: Symptoms occur daily; nighttime awakenings occur $>1\text{ time/week}$.

  • Severe Persistent Asthma: Symptoms occur continually throughout every day; nighttime awakenings occur $>7\text{ times/week}$.

Asthma Diagnostic Testing and Arterial Blood Gas (ABG) Analysis

• Pulse Oximetry:

  • An $\text{SpO}_2 < 90\%$ is a late sign of severe respiratory distress and indicates an acutely unwell client. Used as an immediate baseline upon clinical admission.

• Peak Flow Meter:

  • A small, handheld monitoring device that measures the maximum speed of air a client can forcefully exhale in a single breath (Peak Expiratory Flow Rate - PEFR).

  • Testing Technique: The client inhales deeply, places their mouth tightly around the mouthpiece, and exhales as hard and as fast as possible.

  • Interpretation: Values are judged against predicted normal controls based on height, age, and sex.

    • $>80\%$ of predicted normal: Well-controlled airflow.

    • $50\text{--}80\%$ of predicted normal: Moderate airway obstruction.

    • $40\text{--}50\%$ of predicted normal: Severe airway obstruction.

    • $<25\%$ of predicted normal: Life-threatening airway obstruction.

• Spirometry and Pulmonary Function Tests (PFTs):

  • Used to reveal obstructive patterns and measure reversibility following administration of a short-acting bronchodilator (e.g., albuterol).

  • Forced Expiratory Volume in 1 Second ($\text{FEV}_1$): The volume of air forcefully exhaled during the first second of exhalation. Pre-bronchodilator values are significantly decreased in asthma. An increase in $\text{FEV}_1$ of $>12\%$ post-bronchodilator confirms reversible airway obstruction.

  • Forced Vital Capacity ($\text{FVC}$): The total volume of air exhaled during a complete forced breath. Typically normal or slightly decreased; normalizes post-bronchodilator.

  • $\text{FEV}_1/\text{FVC}$ Ratio: The percentage of total vital capacity exhaled in the first second. During an acute asthma exacerbation, this ratio drops to $<0.70$ ($<70\%$); returns toward normal post-bronchodilator.

• Imaging Studies:

  • Chest X-Ray: Assesses for pulmonary hyperinflation, underlying pulmonary infections, or foreign body aspiration driving symptoms.

  • Chest CT Scan: Utilized for clients who fail to respond to standard asthma treatments to detect subtle anatomical or structural pulmonary abnormalities.

• Arterial Blood Gas (ABG) Diagnostics:

  • $\text{pH}$: Normal range is $7.35\text{--}7.45$. Values $<7.35$ indicate acidemia; values $>7.45$ indicate alkalemia.

  • $\text{PaCO}_2$: Normal range is $35\text{--}45\,\text{mmHg}$. Represents the respiratory component of acid-base balance. Regulated by alveolar ventilation. In respiratory disorders, $\text{pH}$ and $\text{PaCO}_2$ move in opposite directions ("Respiratory Opposite, Metabolic Equal").

  • $\text{PaO}_2$: Normal range is $80\text{--}100\,\text{mmHg}$. Reflects the partial pressure of oxygen dissolved in arterial blood and alveolar oxygen absorption capability.

  • $\text{HCO}_3^-$ (Bicarbonate): Normal range is $21\text{--}28\,\text{mEq/L}$. Represents the renal/metabolic component. Deviations outside this range indicate renal compensation for primary respiratory acid-base imbalances.

  • $\text{SaO}_2$: Normal range is $95\text{--}100\%$. Percentage of hemoglobin sites bound to oxygen.

  • Base Excess: Represents the amount of acid or base required to titrate $1\,\text{L}$ of arterial blood back to a $\text{pH}$ of $7.40$ at $37^\circ\text{C}$. Indicates metabolic deviations.

• Acid-Base Patterns in Respiratory Conditions:

  • Uncompensated Respiratory Acidosis: $\text{pH} < 7.35$, $\text{PaCO}_2 > 45\,\text{mmHg}$, $\text{HCO}_3^-$ normal ($21\text{--}28\,\text{mEq/L}$).

  • Compensated Respiratory Acidosis: $\text{pH}$ normal ($7.35\text{--}7.40$) or borderline low, $\text{PaCO}_2 > 45\,\text{mmHg}$, $\text{HCO}_3^- > 28\,\text{mEq/L}$.

  • Uncompensated Respiratory Alkalosis: $\text{pH} > 7.45$, $\text{PaCO}_2 < 35\,\text{mmHg}$, $\text{HCO}_3^-$ normal ($21\text{--}28\,\text{mEq/L}$).

  • Compensated Respiratory Alkalosis: $\text{pH}$ normal ($7.40\text{--}7.45$) or borderline high, $\text{PaCO}_2 < 35\,\text{mmHg}$, $\text{HCO}_3^- < 21\,\text{mEq/L}$.

• Detailed ABG Case Study Analysis:

  • Client Presentation (08:00 ER): Presents with 6 hours of worsening dyspnea following exercise in cold air. Reports severe chest tightness and an inability to exhale air. Sitting upright in tripod position, visibly anxious, utilizing accessory muscles. Speech limited to 2--3 word phrases. Expiratory wheezing heard throughout all lung fields with a prolonged expiratory phase. Multiple home rescue inhaler doses yielded minimal relief.

  • Vital Signs: Temperature $98.8^\circ\text{F}$, Heart Rate $104\,\text{bpm}$, Respiratory Rate $34\,\text{breaths/min}$, Blood Pressure $146/84\,\text{mmHg}$, $\text{SpO}_2 = 88\%$ on room air.

  • ABG Results: $\text{pH} = 7.30$ (low), $\text{PaCO}_2 = 55\,\text{mmHg}$ (high), $\text{PaO}_2 = 68\,\text{mmHg}$ (low), $\text{HCO}_3^- = 26\,\text{mEq/L}$ (normal), $\text{SaO}_2 = 88\%$ (low).

  • Clinical Interpretation: Uncompensated Respiratory Acidosis. The low $\text{pH}$ and elevated $\text{PaCO}_2$ confirm a primary respiratory acidosis. Normal $\text{HCO}_3^-$ demonstrates lack of renal compensation. Severe bronchoconstriction causes air trapping and failure to exhale $\text{CO}_2$, resulting in acute hypercapnia and acidosis.

  • Pathophysiologic Transition: Early in an asthma attack, clients hyperventilate and blow off $\text{CO}_2$, producing respiratory alkalosis. As respiratory muscles tire from prolonged tachypnea, hypoventilation ensues, causing rising $\text{PaCO}_2$ levels and a transition to respiratory acidosis. This transition is a late, grave sign indicating impending respiratory failure and immediate need for intubation.

Pharmacological Management of Asthma and COPD

• Inhalation Devices and Administration Techniques:

  • Metered-Dose Inhaler (MDI): Delivers a specific pressurized dose of medication. Can be attached to a spacer (a reservoir holding chamber) to slow down the mist and ensure full delivery into the deep lungs rather than depositing in the back of the throat. Essential for pediatric clients.

  • Nebulizer: Converts liquid drug solutions into a continuous fine aerosol mist for inhalation through a mask or mouthpiece.

  • Dry-Powder Inhaler (DPI): Delivers drug as a dry powder. Requires rapid, deep inhalation without canister compression. The device is clicked/turned to load sequential doses.

  • Sequential Administration Rule: When prescribed both a bronchodilator and a corticosteroid inhaler, always administer the short-acting bronchodilator (SABA) first. Wait $5\,\text{minutes}$, then administer the corticosteroid. The bronchodilator opens the smooth muscles of the airway, allowing the corticosteroid to penetrate deeper into the lung tissue.

  • Post-Inhalation Care: Clients must rinse their mouth with water and spit it out after using any inhaled corticosteroid to prevent oral candidiasis (thrush).

• Short-Acting Beta-2 Agonist (SABA): Albuterol:

  • Prototype: Albuterol (Brand name: Ventolin).

  • Mechanism of Action: Rapidly stimulates $\beta_2$-adrenergic receptors in bronchial smooth muscle ($\beta_1$ = 1 Heart, $\beta_2$ = 2 Lungs), causing smooth muscle relaxation and prompt bronchodilation.

  • Clinical Role: Emergency / Rescue Inhaler. First-line agent for acute wheezing, dyspnea, and bronchospasm.

  • Routes: Inhalation aerosol (MDI), nebulizer solution, oral liquid, oral tablets.

  • Side Effects (Sympathetic Nervous System / Fight-or-Flight Activation): Tremors, fine hand shakiness, chest pain, palpitations, tachycardia, nervousness, restlessness, headache, dizziness, insomnia, pediatric hyperactivity, nausea, vomiting.

  • Adverse Effects: Hyperglycemia (requires caution in clients with diabetes mellitus), hypokalemia (causes potassium movement into intracellular space), paradoxical bronchospasm, cardiac arrhythmias, severe hypertension.

  • Drug Interactions: Increased adrenergic toxicity with other sympathomimetics; $\beta$-blockers (e.g., propranolol) antagonize bronchodilating effects; concurrent use with non-potassium-sparing diuretics (furosemide, hydrochlorothiazide) increases the risk of severe hypokalemia.

  • Contraindications: Known hypersensitivity to adrenergic amines.

  • Client Education and Red Flags: Inform provider immediately if shortness of breath is not relieved after taking a dose, if usual doses become ineffective, or if a single inhaler canister is exhausted in less than 2 weeks (indicates dangerously uncontrolled disease).

  • Desired Outcomes: Prompt relief of bronchospasm, improved breath sounds, increased $\text{SpO}_2$.

• Long-Acting Beta-2 Agonist (LABA): Salmeterol:

  • Prototype: Salmeterol.

  • Mechanism of Action: Selectively stimulates $\beta_2$-adrenergic receptors over an extended duration ($12\,\text{hours}$).

  • Clinical Role: Maintenance control and prevention of bronchospasm in asthma and COPD; prevention of exercise-induced asthma. NOT for acute relief or emergency asthma attacks.

  • Route: Dry-powder inhaler (DPI) administered twice daily ($q12h$).

  • Side/Adverse Effects: Prolonged sympathomimetic effects including tremors, palpitations, chest discomfort, persistent trembling, agitation, seizures, tachyarrhythmias, hyperglycemia, hypokalemia, paradoxical bronchospasm.

  • MANDATORY BLACK BOX WARNING: LABAs must NEVER be used as monotherapy for asthma. They must ALWAYS be combined with an inhaled corticosteroid (ICS) or a muscarinic antagonist. Using a LABA alone increases the risk of severe asthma exacerbations and asthma-related death because LABAs do not suppress airway inflammation.

  • Contraindications: Hypersensitivity to salmeterol or milk proteins; treatment of acute bronchospasm.

  • Precautions: Cardiovascular disorders, seizure disorders, diabetes, glaucoma, hyperthyroidism. Safety in children $<4\,\text{years}$ is not established.

• Short-Acting Muscarinic Antagonist (SAMA): Ipratropium:

  • Prototype: Ipratropium.

  • Mechanism of Action: Blocks cholinergic / muscarinic ($\text{M}_3$) receptors in bronchial smooth muscle, inhibiting acetylcholine-induced bronchoconstriction and decreasing mucosal secretions. Possesses anticholinergic properties.

  • Clinical Role: Maintenance therapy for reversible airway obstruction in COPD (chronic bronchitis/emphysema). Off-label adjunct with SABAs during severe acute asthma exacerbations.

  • Routes: MDI aerosol, nebulizer solution.

  • Side Effects: Dry mouth, throat irritation, GI distress, blurred vision, headache, dizziness, nervousness, palpitations, hypotension.

  • Adverse Effects: Anaphylaxis/hypersensitivity, paradoxical bronchospasm, acute urinary retention, worsening of narrow-angle glaucoma.

  • Interactions: Additive anticholinergic side effects when administered with antihistamines or other anticholinergic drugs.

  • Contraindications & Precautions: Hypersensitivity to ipratropium, atropine, or derivatives. Exercise caution in clients with bladder neck obstruction, benign prostatic hyperplasia (BPH), narrow-angle glaucoma, breastfeeding, or elderly clients (who are highly sensitive to anticholinergic effects).

  • Client Education: Suck on sugar-free hard candy or chew sugar-free gum to relieve dry mouth. Report dry mouth or mouth irritation lasting $>2\text{ weeks}$. Report lack of clinical improvement within $30\,\text{minutes}$ of administration.

• Long-Acting Muscarinic Antagonist (LAMA): Tiotropium:

  • Prototype: Tiotropium.

  • Mechanism of Action: Selectively and reversibly inhibits $\text{M}_3$ muscarinic receptors in airway smooth muscle, producing prolonged bronchodilation and reduced mucus production.

  • Clinical Role: Long-term, once-daily maintenance treatment of COPD and asthma. Reduces frequency of exacerbations. Contraindicated for acute bronchospasm.

  • Routes: Soft mist inhaler, dry-powder inhaler (DPI).

  • Side Effects: Dry mouth, hoarseness, cough, rash, tachycardia.

  • Adverse Effects: Paradoxical bronchospasm, acute urinary retention, acute narrow-angle glaucoma, severe hypersensitivity reactions.

  • Interactions: Avoid concomitant administration with ipratropium due to therapeutic duplication and severe anticholinergic toxicity.

• Corticosteroids: Budesonide (Inhaled) and Prednisone (Oral):

  • Prototypes: Budesonide (inhaled), Prednisone (oral tablet/liquid).

  • Mechanism of Action: Potent anti-inflammatory action; inhibits multiple inflammatory cell types (mast cells, eosinophils, neutrophils) and cytokine production, reducing airway edema and hyperresponsiveness.

  • Clinical Role: Prophylactic management of persistent asthma and COPD. Inhaled budesonide is used for chronic daily control. Oral prednisone is reserved for acute exacerbations or severe refractory disease.

  • Inhaled Side Effects: Hoarseness, localized dry mouth, oral candidiasis (thrush).

  • Oral Systemic Adverse Effects: Hyperglycemia, fluid retention, hypertension, peptic ulcer disease, GI bleeding, cataracts, glaucoma, mood alterations, osteoporosis/bone demineralization, severe immunosuppression.

  • ADRENAL CRISIS AND TAPER WARNING: Prolonged oral corticosteroid therapy ($>7\text{ days}$) suppresses the hypothalamic-pituitary-adrenal (HPA) axis, shutting down endogenous adrenal corticosteroid production. Abrupt withdrawal can precipitate a life-threatening adrenal crisis (characterized by severe hypotension, tachycardia, hypoglycemia, hyponatremia, hyperkalemia, cool/clammy skin, and vascular collapse).

  • Tapering Schedule Example: Doses must be gradually tapered off (e.g., prednisone $60\,\text{mg BID} \times 7\text{ days} \rightarrow 40\,\text{mg BID} \times 7\text{ days} \rightarrow 20\,\text{mg BID} \times 7\text{ days} \rightarrow 10\,\text{mg BID} \times 7\text{ days}$).

  • Interactions: Concurrent NSAID use significantly increases the risk of peptic ulcers and GI gastrointestinal bleeding.

  • Contraindications & Precautions: Active systemic fungal infections, severe hepatic impairment. Use with extreme caution in clients with diabetes mellitus (requires frequent blood glucose checks and increased insulin requirements), osteoporosis, active GI ulcers, or baseline immunosuppression.

• Methylxanthines: Theophylline:

  • Prototype: Theophylline.

  • Mechanism of Action: Relaxes smooth muscle surrounding the bronchi and pulmonary blood vessels by inhibiting phosphodiesterase, increasing cyclic-AMP.

  • Clinical Role: Oral long-term control of severe refractory asthma and COPD. Rarely used today due to toxicity.

  • Narrow Therapeutic Index & Toxicity: Requires regular serum blood concentration monitoring. Toxicity manifests at levels close to the therapeutic range.

  • Signs of Toxicity: Severe nausea, persistent vomiting, diarrhea, intense nervousness, severe insomnia, muscular tremors, cardiac dysrhythmias, and grand mal seizures.

  • Interactions: Caffeine and alcohol exacerbate central nervous system and cardiac stimulation. Smoking significantly increases the clearance rate of theophylline. Smokers require higher doses. If a smoking client suddenly stops smoking, the drug level will surge, causing fatal toxicity unless the provider immediately lowers the dosage.

• Mast Cell Stabilizers: Cromolyn:

  • Prototype: Cromolyn.

  • Mechanism of Action: Prevents antigen-induced degranulation of sensitized mast cells, inhibiting the release of histamine and leukotrienes.

  • Clinical Role: Long-term prophylactic control of mild persistent asthma and exercise-induced bronchospasm. Not a bronchodilator; useless during acute attacks.

  • Routes: Nebulizer solution, MDI.

  • Side Effects: Throat irritation, hoarseness, cough, esophagitis, laryngeal/pharyngeal edema, drowsiness, dizziness, pulmonary infiltrates.

  • Precautions: Contraindicated in children $<2\,\text{years}$. Lower initial doses are required in clients with renal or hepatic impairment.

• Leukotriene Modifiers: Montelukast:

  • Prototype: Montelukast.

  • Mechanism of Action: Selectively blocks cysteinyl leukotriene receptor sites ($\text{CysLT}_1$), preventing leukotriene-mediated airway edema, smooth muscle constriction, and inflammatory cell infiltration.

  • Clinical Role: Daily oral prophylactic treatment of chronic asthma and allergic rhinitis.

  • Side Effects: Abdominal pain, dyspepsia, nausea, cough, nasal congestion.

  • Adverse Effects: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) (severe blistering/sloughing skin disorders requiring ICU management), angioedema, systemic eosinophilia, neuropsychiatric events (agitation, depression, sleep disturbances, suicidal ideation and behavior).

  • Interactions: Inducers or inhibitors of CYP3A4 or CYP2C9 may alter plasma drug concentrations.

  • Precautions: Contraindicated in acute asthma attacks. Exercise caution in clients with hepatic impairment, children $<6\,\text{years}$, or phenylketonuria (PKU - inherited disorder preventing metabolism of phenylalanine contained in chewable formulations).

  • Nursing Responsibilities: Monitor respiratory status and lung sounds. Perform routine assessments for behavioral shifts, depression, or emerging suicidal thoughts.

Asthma Stepwise Management and Status Asthmaticus

• Asthma Stepwise Management Overview:

  • Step 1 (Intermittent): As-needed (PRN) low-dose SABA.

  • Step 2 (Mild Persistent): Daily low-dose inhaled corticosteroid (ICS) plus PRN SABA, or PRN concomitant low-dose ICS-SABA.

  • Step 3 (Moderate Persistent): Daily and PRN combination low-dose ICS with formoterol (LABA).

  • Step 4: Daily and PRN combination medium-dose ICS with formoterol.

  • Step 5 (Severe Persistent): Daily medium-to-high dose ICS plus LABA plus LAMA, plus PRN SABA.

  • Step 6: Daily high-dose ICS plus LABA plus systemic oral corticosteroid (prednisone), plus PRN SABA.

• Status Asthmaticus:

  • Definition: A acute, severe, life-threatening asthma attack that is refractory to standard bronchodilator therapy, leading to progressive air trapping, severe hypercapnia, ventilation-perfusion ($V/Q$) mismatch, and acute respiratory failure.

  • Pathophysiologic Deterioration: Severe airway constriction prevents oxygenation and carbon dioxide elimination. Initial hyperventilation causes respiratory alkalosis. As respiratory muscles fatigue, hypercapnia builds, resulting in severe hypoxia and a dangerous shift to uncompensated respiratory acidosis.

  • Risk Factors: Poor client disease comprehension, failure to recognize triggers (e.g., household bleach, animal dander, cigarette smoke), comorbidities (obesity, OSA, CAD), prior status asthmaticus requiring endotracheal intubation, concurrent use of non-selective $\beta$-blockers (e.g., propranolol, which blocks $\beta_2$ pulmonary receptors).

  • Clinical Manifestations: Severe dyspnea, violent coughing, audible wheezing that may progress to a silent chest (absence of air movement), marked intercostal/sternal retractions, prolonged expiratory phase, tachypnea, tachycardia, hypertension, diaphoresis, severe anxiety, restlessness, agitation, and extreme lethargy (indicating impending arrest).

  • Diagnostic Evaluation: $\text{PEFR} < 50\%$ of baseline. A failure to demonstrate $>10\%$ improvement in PEFR after aggressive emergency bronchodilator therapy requires immediate hospital admission. ABG reveals rising $\text{PaCO}_2$ and falling $\text{pH}$.

  • Emergency Nursing Interventions:

    • Place client on continuous cardiac rhythm and pulse oximetry monitoring.

    • Administer high-flow humidified oxygen to maintain $\text{SpO}_2 > 90\%$ ($95\text{--}100\%$ target).

    • Administer continuous nebulized SABAs (albuterol) combined with SAMAs (ipratropium).

    • Administer immediate IV systemic corticosteroids (oral steroids are inadequate due to delayed onset).

    • Provide IV hydration to liquefy thick, tenacious bronchial secretions and promote expectoration.

    • Avoid aggressive sedation; monitor continuously for signs of fatigue.

  • Evaluation Criteria: Clinical recovery is confirmed by a sustained improvement in symptoms lasting $\ge 30\,\text{minutes}$ after bronchodilator administration, alongside a $\text{PEFR} > 70\%$ of predicted. If the client deteriorates or $\text{PaCO}_2$ rises, assist immediately with endotracheal intubation and mechanical ventilation.

Chronic Obstructive Pulmonary Disease (COPD)

• Definition and Pathophysiology:

  • COPD is a progressive, irreversible airway disease characterized by chronic airflow limitation caused by toxic gas or particle exposure (primarily long-term tobacco smoke).

  • Involves chronic inflammatory infiltration of T-lymphocytes, neutrophils, and macrophages throughout the pulmonary vasculature and parenchyma, leading to loss of pulmonary elastic recoil, parenchymal destruction, airway fibrosis, hypersecretion of mucus, and structural narrowing.

• COPD Subtypes:

  • Emphysema: Permanent enlargement and destruction of the alveoli distal to the terminal bronchioles (the acinus, including respiratory bronchioles, alveolar ducts, and alveolar sacs). Loss of elastic recoil leads to severe bullae formation and air trapping on exhalation.

  • Chronic Bronchitis: Characterized by a chronic productive cough lasting at least 3 consecutive months per year for 2 consecutive years. Involves hypertrophy of mucus-secreting glands, ciliary dysfunction, severe bronchial wall inflammation, and persistent mucus plugging. Damaged pulmonary cells lose the ability to clear pathogens, predisposing clients to recurrent pulmonary infections.

• Calculating Smoking Pack-Years:

  • $\text{Pack-Years} = (\text{Packs smoked per day}) \times (\text{Years of smoking})$.

  • Example 1: 1 pack/day for 10 years = $10\,\text{pack-years}$.

  • Example 2: 2 packs/day for 15 years = $30\,\text{pack-years}$.

  • Example 3: 0.5 packs/day for 20 years = $10\,\text{pack-years}$.

  • Manifestations of COPD typically emerge after a cumulative threshold of $\ge 20\,\text{pack-years}$.

• Risk Factors:

  • Active or passive tobacco smoke exposure (the primary risk factor).

  • Female sex, advanced age.

  • Occupational exposure to organic/inorganic dusts, coal dust, chemical fumes, and ambient air pollution.

  • Hypersensitive airway responsiveness, persistent untreated asthma, genetic Alpha-1 Antitrypsin (AAT) deficiency.

• Clinical Presentation & Phenotypes:

  • Pink Puffer (Emphysema Phenotype):

    • Pathophysiology: Primary structural issue is alveolar destruction and air trapping.

    • Presentation: Pink-complexioned skin, tachypneic, severe dyspnea, minimal cough with scanty sputum.

    • Physical Findings: Prominent barrel chest (increased anteroposterior-to-lateral chest diameter of 1:1 due to chronic hyperinflation), pursed-lip breathing (creates backpressure to keep collapsed airways open during exhalation), tripod positioning (leaning forward with hands on knees/table to leverage accessory chest muscles), severe cachexia (profound muscle wasting due to high metabolic caloric burn required just to breathe).

  • Blue Bloater (Chronic Bronchitis Phenotype):

    • Pathophysiology: Primary structural issue is bronchial inflammation, mucus obstruction, and chronic cyanosis.

    • Presentation: Marked cyanosis (bluish skin tint due to severe hypoxemia), chronic productive cough with copious purulent sputum.

    • Physical Findings: Obese body habitus, peripheral edema secondary to right-sided heart failure (Cor Pulmonale), widespread pulmonary crackles and rhonchi.

• Diagnostic Evaluation:

  • CAPTURE Survey: 5-item screening questionnaire assessing exposure, seasonal breathing shifts, activity limitation, and lost work days. Scores range from 0 to 6. A score of $5\text{--}6$ indicates high COPD risk requiring immediate diagnostic spirometry.

  • Diagnostic Spirometry: Gold Standard. Demonstrates persistent, non-reversible airflow obstruction post-bronchodilator administration. The $\text{FEV}_1/\text{FVC}$ ratio drops to $<0.70$ ($<70\%$).

  • Diagnostic Imaging: Chest X-ray reveals hyperinflated lungs, flattened diaphragms, and enlarged retrosternal air spaces. CT scans assess bullae formation and bronchiectasis.

  • Laboratory Testing: Serum Alpha-1 Antitrypsin (AAT) levels; CBC to assess for compensatory polycythemia (elevated RBCs due to chronic hypoxia); baseline ABG showing mild baseline compensated hypercapnia.

• Target Oxygen Saturation in COPD:

  • Target $\text{SpO}_2$ is $88\text{--}92\%$.

  • Physiologic Rationale: Clients with chronic COPD retain $\text{CO}_2$ long-term, causing their central chemoreceptors to desensitize to hypercapnia. Their drive to breathe shifts to hypoxic drive (driven by low $\text{PaO}_2$ levels). Administering excessive oxygen abolishes their hypoxic respiratory drive, inducing severe hypoventilation, severe hypercapnic encephalopathy, $\text{CO}_2$ narcosis, and respiratory arrest.

• Medical Management & Nursing Interventions:

  • First-Line Pharmacotherapy: Maintenance long-acting bronchodilator combination therapy (LABA + LAMA combination inhalers) is preferred for baseline management. SABAs are reserved for acute breakthrough dyspnea.

  • Immunizations: Annual Influenza vaccine, Pneumococcal vaccine (for all adults $\ge 65\,\text{years}$ or those younger with chronic pulmonary disease), and RSV vaccine (for adults $\ge 60\,\text{years}$).

  • Pulmonary Rehabilitation & Breathing Techniques: Teach pursed-lip breathing and diaphragmatic breathing. Instruct in energy conservation strategies during ADLs.

  • Smoking Cessation Education:

    • Within 1 week: Blood oxygen levels improve, $\text{CO}_2$ levels normalize, breathing becomes easier.

    • Within 1 month: Exertional stamina increases, stair climbing becomes easier, coughing and sinus congestion decline, peripheral circulation improves.

    • Long-term: Pulmonary infection risks decrease drastically, comorbidity progression slows, quality of life improves.

Atelectasis

• Definition & Mechanism:

  • Atelectasis is the collapse or closure of alveoli within the lung tissue, resulting in reduced or absent gas exchange across affected alveolar-capillary membranes.

  • Primary Etiologies: Postoperative shallow breathing (hypoventilation), airway obstruction by mucus plugs or tumors, external mechanical compression (pleural effusion), or prolonged postoperative immobility.

• Clinical Presentation:

  • Dyspnea, tachypnea, increased work of breathing.

  • Diminished or completely absent breath sounds over the collapsed lung segments.

  • Fine end-inspiratory crackles over affected areas.

  • Hypoxemia ($\text{SpO}_2 < 90\%$, low $\text{PaO}_2$).

  • Ineffective, weak, or absent cough capability.

  • Low-grade postoperative fever (atelectasis is the primary cause of early postoperative fever).

• Diagnostic Findings:

  • Chest X-Ray: The definitive diagnostic tool. Demonstrates localized subsegmental, lobar, or lung collapse, loss of pulmonary volume, elevated diaphragm on the affected side, and potential mediastinal shift toward the collapsed side.

  • CBC: May show elevated white blood cell count (leukocytosis) if secondary bacterial pneumonia develops within collapsed tissue.

• Priority Nursing Interventions:

  • Incentive Spirometry (IS): Instruct the client to perform incentive spirometry 10 times per hour while awake.

    • Technique: Client sits upright, exhales completely, places lips tightly around mouthpiece, and inhales slowly and deeply (sucking motion) to elevate the visual indicator, holding their breath for $3\text{--}5\,\text{seconds}$ at peak inspiration.

  • Pulmonary Hygiene: Deep breathing and controlled coughing exercises; chest physiotherapy (percussion/vibration) to break up thick secretions.

  • Mobility: Turn and reposition the client at least every 2 hours; enforce early postoperative ambulation.

  • Hydration & Pain Control: Maintain adequate oral/IV fluid intake to thin pulmonary secretions. Administer prescribed analgesics to control surgical incision pain, and teach the client to splint their surgical incision with a pillow during coughing exercises to minimize pain.

Pneumonia

• Definition and Classification:

  • Pneumonia is an acute inflammatory infection of the lung parenchyma caused by bacteria, viruses, fungi, or aspirates, filling alveolar spaces with exudative fluid, inflammatory cells, and pus.

  • Community-Acquired Pneumonia (CAP): Acquired in the community setting or diagnosed within $<48\,\text{hours}$ of hospital admission.

  • Hospital-Acquired Pneumonia (HAP): Diagnosed $\ge 48\,\text{hours}$ after hospital admission, not present at the time of admission.

  • Ventilator-Associated Pneumonia (VAP): Arises $\ge 48\,\text{hours}$ following endotracheal intubation and mechanical ventilation.

• Pathophysiology & Transmission:

  • Infectious pathogens enter the lower respiratory tract via inhalation, hematogenous spread, direct extension, or micro-aspiration of oropharyngeal secretions (common in elderly, sedated, or dysphagic clients).

  • Alveoli become severely inflamed and congested with purulent fluid, resulting in consolidation of pulmonary tissue (lobar pneumonia or patchy bronchopneumonia) and severe gas exchange impairment. Advanced cases can form localized lung abscesses or empyema requiring Video-Assisted Thoracoscopic Surgery (VATS) or bedside needle drainage.

• Risk Factors:

  • Age $\ge 65\,\text{years}$, chronic pulmonary disease (COPD, asthma, cystic fibrosis), heart failure, lung cancer.

  • Prolonged immobility, recent surgery, baseline immunocompromised status (HIV, chemotherapy, chronic steroid use), diabetes mellitus.

  • Active smoking, alcohol abuse, opioid use (suppresses cough reflex).

• Clinical Presentation:

  • Systemic symptoms: High fever, rigors/chills, malaise, myalgias, anorexia, diaphoresis.

  • Respiratory symptoms: Productive cough with purulent, rusty, or blood-tinged sputum; pleuritic chest pain (sharp pain localized to the infected lobe that worsens with deep inspiration or coughing); dyspnea; tachypnea; tachycardia.

  • Physical Exam: Dullness to percussion over the consolidated lung lobe; bronchial breath sounds over peripheral fields; coarse crackles, rales, or rhonchi; decreased arterial oxygen saturation.

• Complications: Empyema, lung abscess, superinfections, Acute Respiratory Distress Syndrome (ARDS), bacteremia, septic shock, multi-organ failure.

• CRITICAL DIAGNOSTIC AND ANTIBIOTIC PROTOCOL:

  • Diagnostic Testing: Chest X-ray demonstrating pulmonary lobar consolidation or infiltrates; elevated WBC count with a left shift (increased immature bands); elevated inflammatory markers (C-reactive protein, ESR, procalcitonin).

  • GOLDEN RULE FOR CULTURES: ALWAYS obtain blood cultures (from 2 separate sites) and sputum cultures BEFORE administering the first dose of antibiotic therapy.

  • Rationale: Administering antibiotics prior to culture collection sterilizes or skews culture samples, preventing identification of the causative organism and sensitivity testing. Empirical broad-spectrum antibiotic coverage (e.g., IV Zosyn [piperacillin/tazobactam] plus Vancomycin) is started immediately after cultures are drawn, pending final $48\text{--}72\,\text{hour}$ culture results.

• Nursing Care & Client Education:

  • Position client with Head of Bed elevated ($30\text{--}45^\circ$) to promote lung expansion.

  • Encourage fluid intake ($2\text{--}3\,\text{L/day}$ unless contraindicated) to thin thick secretions; provide humidified oxygen.

  • Client Teaching: Emphasize completing the entire prescribed course of antibiotics, even if symptoms completely resolve after a few days. Premature discontinuation fosters mutational survival of virulent bacteria, producing drug-resistant strains. Practice cough etiquette (coughing into the inner crook of the elbow), perform hand hygiene, and obtain annual influenza and pneumococcal immunizations.

Pneumothorax

• Definition & Pathophysiology:

  • A pneumothorax occurs when air enters the pleural cavity between the visceral and parietal pleura, disrupting the normal negative intrapleural pressure that keeps the lung expanded. The accumulated air exerts positive pressure on the lung, causing partial or total collapse.

• Classification & Etiologies:

  • Traumatic Pneumothorax: Caused by penetrating or blunt chest trauma (rib fractures, stab wounds, gunshot wounds, motor vehicle collisions). Can form a one-way tissue valve that lets air enter the pleural space during inspiration but prevents its escape during expiration.

  • Primary Spontaneous Pneumothorax: Occurs unexpectedly without underlying lung disease. Typically affects tall, thin young males. Caused by the spontaneous rupture of small subpleural air blisters (blebs). Cannabis/tobacco smoking and Marfan syndrome markedly increase risk.

  • Secondary Spontaneous Pneumothorax: Occurs as a complication of underlying pulmonary disease (COPD bullae rupture, tuberculosis, cystic fibrosis, necrotizing pneumonia, lung cancer).

  • Open Pneumothorax: Air moves freely in and out of the pleural cavity through a large, open chest wall defect ("sucking chest wound").

  • Iatrogenic Pneumothorax: Occurs as an unintended complication of medical procedures (central venous line insertion, thoracentesis, lung biopsy, or high-pressure mechanical ventilation [barotrauma]).

  • Tension Pneumothorax (LIFE-THREATENING EMERGENCY): Air rapidly enters the pleural space with every inspiration but cannot escape. Intrapleural pressure rises dramatically, causing complete collapse of the ipsilateral lung and shifting the mediastinum (heart, trachea, great vessels) toward the unaffected side (mediastinal shift). Compression of the vena cava severely decreases venous return, leading to sudden drop in cardiac output, shock, and cardiac arrest.

• Clinical Presentation:

  • Sudden, sharp pleuritic chest pain radiating to the ipsilateral shoulder.

  • Severe dyspnea, tachypnea, anxiety, restlessness.

  • Asymmetrical chest wall movement (the affected side fails to expand on inspiration).

  • Hyper-resonant percussion note over the hyper-inflated pleural air cavity.

  • Significantly diminished or completely absent breath sounds on the affected side.

  • Subcutaneous emphysema (crepitus): Air trapped under the skin that produces a crackling/crunchy sensation upon palpation.

  • Red Flags for Tension Pneumothorax: Severe tachycardia ($>134\,\text{beats/min}$), profound hypotension, tracheal deviation away from the affected side, marked Jugular Venous Distension (JVD), and central cyanosis.

• Diagnostic Standard:

  • Chest X-Ray: Gold standard. Demonstrates a radiolucent (black) pleural space lacking lung markings, a visible visceral pleural line representing the collapsed lung margin, and mediastinal displacement.

• Emergency & Definitive Interventions:

  • Tension Pneumothorax Emergency Action: Perform immediate needle decompression (inserting a large-bore needle into the 2nd intercostal space at the midclavicular line) to release trapped air, followed immediately by chest tube insertion.

  • Chest Tube Drainage System Setup: A chest tube is inserted into the 5th intercostal space (midaxillary line) and connected to a closed chest drainage system with wet or dry suction set to $-10\text{ to }-20\,\text{cmH}_2\text{O}$.

• Chest Tube System Nursing Care & Emergency Troubleshooting:

  • Collection Chamber: Monitor and mark output hourly initially, then every $4\text{--}12\,\text{hours}$. Document color and character (sanguineous, serosanguineous).

  • Water Seal Chamber: Must title (rise on inspiration and fall on expiration in a spontaneously breathing client). Cessation of tidaling indicates either full re-expansion of the lung (confirmed by chest X-ray) or an obstruction/kink in the tubing. Continuous bubbling in the water seal chamber indicates an active AIR LEAK in the system.

  • CRITICAL EMERGENCY 1: Chest Tube Pulled Out of Patient's Chest:

    • Immediately cover the insertion site with an occlusive sterile dressing (e.g., petroleum gauze) TAPED ON THREE SIDES ONLY.

    • Rationale: Taping on 3 sides creates a flutter valve—allowing air to escape the pleural space during exhalation while preventing atmospheric air from being sucked back in during inhalation. Taping all 4 sides would convert the site into a closed space, inducing a fatal tension pneumothorax.

  • CRITICAL EMERGENCY 2: Tubing Disconnects from Drainage Unit:

    • Immediately submerge the exposed distal end of the chest tube into a bottle of sterile water or sterile saline ($2\text{--}3\,\text{cm}$ deep).

    • Rationale: Establishes an emergency temporary water seal to prevent atmospheric air from entering the pleural cavity while a new sterile drainage unit is set up.

• Management Based on Pneumothorax Size:

  • Primary Spontaneous ($<2\,\text{cm}$, asymptomatic): Discharge home with conservative observation; follow-up in 2--4 weeks.

  • Secondary Spontaneous ($<1\,\text{cm}$, no dyspnea): Hospital admission, high-flow oxygen, observe for 24 hours.

  • Secondary Spontaneous ($1\text{--}2\,\text{cm}$): Needle aspiration followed by supplemental oxygen.

  • Secondary Spontaneous ($>2\,\text{cm}$ or symptomatic): Immediate chest tube insertion.

Tuberculosis (TB)

• Etiology & Transmission:

  • Caused by the acid-fast bacillus Mycobacterium tuberculosis.

  • Transmitted exclusively from person to person via micro-airborne droplets aerosolized when an individual with active pulmonary TB coughs, sneezes, speaks, or sings.

  • Inhaled bacilli enter the alveoli and are engulfed by macrophages, forming calcified collagen-encased granulomatous lesions known as tubercles. Can remain latent for years. Infectivity drops significantly after $2\text{--}3\,\text{weeks}$ of continuous multi-drug antitubercular therapy.

• Priority Hospital Infection Control Protocols:

  • Any client presenting with suspected or confirmed active pulmonary TB must IMMEDIATELY be placed on Airborne Precautions.

  • Place client in a Negative-Pressure Isolation Room (Negative Airflow Room) that exhausts air directly outside or through HEPA filtration, performing at least 6--12 air exchanges per hour.

  • Healthcare workers MUST wear a properly fit-tested N95 respirator mask (or PAPR system) before entering the room.

  • If the client must be transported outside the negative pressure room for diagnostic tests, the client must wear a standard surgical mask during transport.

• Risk Factors:

  • Close contact with an individual holding an active TB infection.

  • Immunosuppressed status (especially HIV/AIDS infection).

  • Substance abuse (alcoholism, IV drug use).

  • Residents or employees of high-density congregate settings (prisons, long-term care facilities, homeless shelters, university dormitories).

  • Healthcare workers; unhoused individuals; advanced age; travel or emigration from TB-endemic regions (Asia, Africa, Latin America, Eastern Europe).

• Clinical Presentation:

  • Persistent cough lasting $>3\,\text{weeks}$.

  • Sputum production that is purulent or mucopurulent with blood streaks (hemoptysis).

  • Low-grade afternoon fever (a characteristic hallmark).

  • Profuse night sweats.

  • Unintentional weight loss, anorexia, severe fatigue, lethargy, exertional dyspnea, pleuritic chest pain.

  • Elderly Presentation: Atypical presentation including confusion/altered mentation, anorexia, and weight loss without classic fever.

• Diagnostic Tests:

  • Acid-Fast Bacilli (AFB) Smear and Culture: Gold Standard for confirming active disease. Requires collection of 3 consecutive early-morning sputum samples on separate days. A positive acid-fast stain confirms preliminary diagnosis; positive culture provides definitive diagnosis.

  • Nucleic Acid Amplification Testing (NAAT): Rapid diagnostic test detecting M. tuberculosis DNA and rifampin resistance within hours.

  • QuantiFERON-TB Gold / T-Spot: Blood assays measuring interferon-gamma release. Highly specific; unaffected by prior Bacille Calmette-Guérin (BCG) vaccination.

  • Mantoux PPD Skin Test: Intradermal injection of $0.1\,\text{mL}$ of purified protein derivative read $48\text{--}72\,\text{hours}$ later. Measured strictly by inspecting and palpating the hard, raised area of induration in millimeters (ignore flat erythema/redness):

    • $\ge 5\,\text{mm}$ Induration: Positive for high-risk groups (HIV-infected, recent contact with active TB, organ transplant recipients, immunosuppressed).

    • $\ge 10\,\text{mm}$ Induration: Positive for moderate-risk groups (recent immigrants from high-prevalence countries, IV drug users, residents/employees of high-risk congregate settings, children $<5\,\text{years}$).

    • $\ge 15\,\text{mm}$ Induration: Positive for low-risk individuals / general population.

  • Follow-up: A positive PPD or interferon-gamma blood test indicates exposure and infection, but does not differentiate latent vs active disease. A Chest X-Ray must be performed next to rule out active pulmonary lesions.

• Antitubercular Pharmacotherapy (The RIPE Regimen):

  • Treatment lasts 6 to 12 months. Due to high rates of non-compliance and emerging multi-drug resistance, the CDC strongly recommends Directly Observed Therapy (DOT)—where a health department worker or trained professional directly watches the client swallow every drug dose.

  • 1. Isoniazid (INH):

    • Action: Bactericidal; inhibits mycolic acid synthesis in the mycobacterial cell wall.

    • Adverse Effects: Severe hepatotoxicity (monitor ALT/AST labs); peripheral neuropathy (numbness, tingling, burning pain in extremities caused by pyridoxine depletion).

    • Nursing Action: Administer daily Vitamin B6 (pyridoxine) supplements to prevent peripheral neuropathy. Strictly avoid alcohol.

  • 2. Pyrazinamide (PZA):

    • Action: Bactericidal agent used in the intensive initial 2-month phase to shorten total treatment duration from 9 to 6 months.

    • Adverse Effects: Severe hepatotoxicity, hyperuricemia, gouty arthritis.

    • Nursing Action: Monitor liver enzymes (ALT/AST) and serum uric acid. Avoid alcohol.

  • 3. Ethambutol (EMB):

    • Action: Bacteriostatic; inhibits RNA synthesis and cell wall assembly.

    • Adverse Effects: Optic Neuritis (inflammation of the optic nerve causing loss of visual acuity and inability to discriminate red from green colors).

    • Nursing Action: Perform baseline and periodic visual acuity and color vision testing. Instruct client to report any changes in vision immediately (drug must be stopped to prevent permanent blindness).

  • 4. Rifampin (RIF):

    • Action: Bactericidal; inhibits DNA-dependent RNA polymerase.

    • Adverse Effects: Hepatotoxicity, jaundice, severe GI distress.

    • CHARACTERISTIC SIDE EFFECT: Causes a harmless orange-red discoloration of body fluids (urine, sweat, tears, saliva, sputum). Warn clients that soft contact lenses will be permanently stained.

    • Nursing Action: Monitor ALT/AST. Instruct client to strictly avoid alcohol and acetaminophen (Tylenol) to prevent compounding liver failure.

• Discontinuation of Airborne Isolation Criteria:

  • The client is considered non-infectious and may be removed from airborne isolation only when they meet ALL of the following: (1) Received continuous compliant multi-drug therapy for at least 2--3 weeks, (2) Clinical symptoms (cough, fever) have significantly improved, and (3) Three consecutive negative AFB sputum smears collected $8\text{--}24\,\text{hours}$ apart, with at least one early-morning specimen.